DPP4 and dementia: The intention-to-treat analysis showed no dementia risk difference between GLP1 receptor agonist and DPP4 inhibitor initiation; however, continuous use of GLP1 receptor agonists versus DPP4 inhibitors was associated with dementia risk reduction.